Optimized dose schedule of rucaparib and liposomal irinotecan/5‐fluorouracil in metastatic gastrointestinal cancers: A phase 1 study
This optimized dosing schedule successfully established the MTD for RUB with nal-IRI and 5-FU, overcoming prior challenges with PARP inhibitor and irinotecan combinations. The promising ORR and DCR support further evaluation of this regimen in advanced GI malignancies.
Authors
- Sarah Bruggeman
- Robert R. McWilliams (ORCID: https://orcid.org/0000-0002-8199-5040)
- Mitesh J. Borad (ORCID: https://orcid.org/0000-0003-2700-2658)
- Wen Wee Ma (ORCID: https://orcid.org/0000-0001-5899-4034)
- Tyler Zemla (ORCID: https://orcid.org/0009-0005-2390-3557)
- Christina Wu (ORCID: https://orcid.org/0000-0001-5922-5392)
- Alexandra Krivonos
- Brandy L. Jaszewski
- Cody R. Eslinger (ORCID: https://orcid.org/0000-0002-8057-0841)
- Olatunji B. Alese (ORCID: https://orcid.org/0000-0001-8079-4725)
- Bassel F. El‐Rayes (ORCID: https://orcid.org/0000-0002-2661-5746)
- Mohamad Bassam Sonbol (ORCID: https://orcid.org/0000-0002-6931-242X)
- Daniel H. Ahn (ORCID: https://orcid.org/0000-0002-0161-4018)
- Fang‐Shu Ou (ORCID: https://orcid.org/0000-0003-1267-8735)
- Daniel Walden (ORCID: https://orcid.org/0000-0001-7238-6094)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Numrah Fadra
- Timothy J. Hobday (ORCID: https://orcid.org/0000-0002-9877-3372)
- Thorvardur Halfdanarson
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Emory University (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1002/cncr.70184
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00